Foldi, Julia Silber, Andrea Reisenbichler, Emily Singh, Kamaljeet Fischbach, Neal Persico, Justin Adelson, Kerin Katoch, Anamika Horowitz, Nina Lannin, Donald
...
Published in
npj Breast Cancer
The goal of this Phase I/II trial is to assess the safety and efficacy of administering durvalumab concurrent with weekly nab-paclitaxel and dose-dense doxorubicin/cyclophosphamide (ddAC) neoadjuvant therapy for stages I–III triple-negative breast cancer. The primary endpoint is pathologic complete response (pCR:ypT0/is, ypN0). The response was cor...
Roelands, Jessica Mall, Raghvendra Almeer, Hossam Thomas, Remy Mohamed, Mahmoud G. Bedri, Shahinaz Al-Bader, Salha Bujassoum Junejo, Kulsoom Ziv, Elad Sayaman, Rosalyn W.
...
Published in
npj Breast Cancer
Breast cancer largely dominates the global cancer burden statistics; however, there are striking disparities in mortality rates across countries. While socioeconomic factors contribute to population-based differences in mortality, they do not fully explain disparity among women of African ancestry (AA) and Arab ancestry (ArA) compared to women of E...
Martínez-Sáez, Olga Pascual, Tomás Brasó-Maristany, Fara Chic, Nuria González-Farré, Blanca Sanfeliu, Esther Rodríguez, Adela Martínez, Débora Galván, Patricia Rodríguez, Anna Belén
...
Published in
npj Breast Cancer
Circulating tumor DNA (ctDNA) levels may predict response to anticancer drugs, including CDK4/6 inhibitors and endocrine therapy combinations (CDK4/6i+ET); however, critical questions remain unanswered such as which assay or statistical method to use. Here, we obtained paired plasma samples at baseline and week 4 in 45 consecutive patients with adv...
McAndrew, Nicholas P. Bottalico, Lisa Mesaros, Clementina Blair, Ian A. Tsao, Patricia Y. Rosado, Jennifer M. Ganguly, Tapan Song, Sarah J. Gimotty, Phyllis A. Mao, Jun J.
...
Published in
npj Breast Cancer
Chronic inflammation has been a proposed mechanism of resistance to aromatase inhibitors in breast cancer. Stratifying by HER2 status, a matched case-control study from the Wellness After Breast Cancer-II cohort was performed to assess whether or not elevated serum inflammatory biomarkers (C-Reactive protein [CRP], interleukin-6 [IL-6], and serum a...
Walsh, Tom Gulsuner, Suleyman Lee, Ming K. Troester, Melissa A. Olshan, Andrew F. Earp, H. Shelton Perou, Charles M. King, Mary-Claire
Published in
npj Breast Cancer
The Carolina Breast Cancer Study (CBCS) phases I–II was a case-control study of biological and social risk factors for invasive breast cancer that enrolled cases and controls between 1993 and 1999. Case selection was population-based and stratified by ancestry and age at diagnosis. Controls were matched to cases by age, self-identified race, and ne...
Akhand, Saeed S. Chen, Hao Purdy, Stephen Connor Liu, Zian Anderson, Joshua C. Willey, Christopher D. Wendt, Michael K.
Published in
npj Breast Cancer
Trastuzumab-emtansine (T-DM1) is an antibody-drug conjugate (ADC) that efficiently delivers a highly potent microtubule inhibitor to HER2 overexpressing cells. Herein, we utilize HER2 transformed human mammary epithelial cells (HME2) to demonstrate in vitro and in vivo response and recurrence upon T-DM1 treatment. Continuous in vitro dosing of HME2...
Wang, Jingyi Ma, Ge Ge, Han Han, Xu Mao, Xinrui Wang, Xinyang Veeramootoo, Jordee Selvamanee Xia, Tiansong Liu, Xiaoan Wang, Shui
...
Published in
npj Breast Cancer
Liquid biopsy is noninvasive and convenient to detect cancer-derived materials in blood or other body fluids. The aim of this study was to identify tRNA-derived small RNAs (tsRNAs) in plasma that could distinguish patients with breast cancer (BC) from healthy controls. Basing on high-throughput sequencing, 15 significantly upregulated tsRNAs were s...
Schettini, Francesco Chic, Nuria Brasó-Maristany, Fara Paré, Laia Pascual, Tomás Conte, Benedetta Martínez-Sáez, Olga Adamo, Barbara Vidal, Maria Barnadas, Esther
...
Published in
npj Breast Cancer
Novel antibody-drug conjugates against HER2 are showing high activity in HER2-negative breast cancer (BC) with low HER2 expression (i.e., 1+ or 2+ and lack of ERBB2 amplification). However, the clinical and molecular features of HER2-low BC are yet to be elucidated. Here, we collected retrospective clinicopathological and PAM50 data from 3,689 pati...
Wehrse, E. Sawall, S. Klein, L. Glemser, P. Delorme, S. Schlemmer, H.-P. Kachelrieß, M. Uhrig, M. Ziener, C. H. Rotkopf, L. T.
...
Published in
npj Breast Cancer
Conventional CT scanners use energy-integrating detectors (EIDs). Photon-counting detector (PCD) computed tomography (CT) utilizes a CT detector technology based on smaller detector pixels capable of counting single photons and in addition discriminating their energy. Goal of this study was to explore the potential of higher spatial resolution for ...
Løkkegaard, Sanne Elias, Daniel Alves, Carla L. Bennetzen, Martin V. Lænkholm, Anne-Vibeke Bak, Martin Gjerstorff, Morten F. Johansen, Lene E. Vever, Henriette Bjerre, Christina
...
Published in
npj Breast Cancer
Resistance to endocrine therapy in estrogen receptor-positive (ER+) breast cancer is a major clinical problem with poorly understood mechanisms. There is an unmet need for prognostic and predictive biomarkers to allow appropriate therapeutic targeting. We evaluated the mechanism by which minichromosome maintenance protein 3 (MCM3) influences endocr...
